(MENAFN- GlobeNewsWire - Nasdaq) Key market opportunities in liquid biopsy for early cancer detection include increasing demand for non-invasive diagnosis, driven by rising cancer cases and precision oncology trends. Advancements in multi-cancer assays, minimal residual disease detection, and decentralized platforms enhance clinical application, supporting widespread adoption in diagnostics.

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Liquid Biopsy For Early Cancer Detection And Monitoring Market Size, Share & Trends Analysis Report By Biomarker (Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs)), By Technology, By Cancer, By End Use, By Region, And Segment Forecasts, 2025 - 2033" report has been added to ResearchAndMarkets's offering.
The global liquid biopsy for early cancer detection and monitoring market size was estimated at USD 2.23 billion in 2024 and is projected to reach USD 6.20 billion by 2033, growing at a CAGR of 12.14% from 2025 to 2033. This market focuses on diagnostic solutions designed for the early and accurate detection of various cancers, enabling timely intervention and improved patient outcomes.

Technologies within this segment include platforms for analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers from body fluids, offering a less invasive alternative to tissue biopsies. These solutions are increasingly integrated into oncology practices for early detection, therapy selection, and disease monitoring across clinical and research environments.
The adoption of liquid biopsy is supported by rising cancer incidence and the growing need for non-invasive methods that allow frequent monitoring with minimal discomfort to patients. The ability to detect tumor-related genetic changes in real time provides oncologists with valuable information for treatment decisions and early intervention strategies.
Moreover, the adoption of liquid biopsy is increasing as the field moves toward precision oncology, where genomic and molecular insights inform treatment decisions and long-term care. High-sensitivity techniques supported by next-generation sequencing, digital PCR workflows, and advancing bioinformatics tools help detect low-frequency variants, minimal residual disease, and emerging resistance signals. Additionally, efforts in multi-cancer early detection and assay panels that analyze multiple biomarkers such as DNA, RNA fragments, epigenetic signatures, and extracellular vesicle content are broadening clinical applications from late-stage management to risk assessment and population-level screening.
Furthermore, the market is shaped by evidence-generation programs, regulatory support, and payer assessments that focus on clinical value and cost-effectiveness compared to traditional tissue-based methods. Challenges still exist, such as variations in assay performance across platforms, a lack of standardization in sample collection and analysis, and difficulties in interpreting weak signals in early disease stages. Limited reimbursement in some regions also impacts accessibility. Ongoing clinical trials, real-world studies, and data-sharing initiatives are expected to bring clarity, improve guidelines, and promote wider adoption of liquid biopsy for early detection and continuous cancer monitoring.
Innovation in liquid biopsy for early detection and monitoring emphasizes accuracy, accessibility, and clinical applicability. Multi-omics integration, AI-driven interpretation, and advanced sequencing transform detection and tracking processes, enabling higher sensitivity for early-stage disease and more personalized treatment planning.
Developments such as multi-cancer detection assays and near-patient platforms aim to extend liquid biopsies outside centralized facilities, enhancing convenience and supporting large-scale screening initiatives. Progress in minimal residual disease detection and continuous monitoring is expected to drive broader clinical uptake and strengthen liquid biopsy's role in oncology care.
Global Liquid Biopsy For Early Cancer Detection And Monitoring Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global liquid biopsy for early cancer detection and monitoring market based on biomarker, technology, cancer, end use, and region.

This report addresses:

• Market intelligence to enable effective decision-making
• Market estimates and forecasts from 2018 to 2030
• Growth opportunities and trend analyses
• Segment and regional revenue forecasts for market assessment
• Competition strategy and market share analysis
• Product innovation listing for you to stay ahead of the curve

Key Attributes:

Report Attribute	Details
No. of Pages	136
Forecast Period	2024 - 2033
Estimated Market Value (USD) in 2024	$2.23 Billion
Forecasted Market Value (USD) by 2033	$6.2 Billion
Compound Annual Growth Rate	12.1%
Regions Covered	Global

Key Topics Covered:
Chapter 1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Methodology And Scope
Chapter 2. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Executive Summary
2.1. Market Snapshot
2.2. Biomarker And Technology Snapshot
2.3. Cancer Snapshot
2.4. End Use Snapshot
2.5. Competitive Landscape Snapshot
Chapter 3. Liquid Biopsy For Early Cancer Detection And Monitoring Market Variables, Trends, & Scope
3.1. Market Segmentation And Scope
3.2. Market Lineage Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Growing Demand For Non-Invasive Cancer Screening
3.4.2. Integration Of Advanced Technologies
3.4.3. Increasing Clinical Adoption And Regulatory Approvals
3.5. Market Restraint Analysis
3.5.1. High Cost Of Liquid Biopsy Tests And Infrastructure
3.5.2. Analytical And Clinical Validation Challenges
3.6. Porter's Five Forces Analysis
3.7. Pestle Analysis
3.8. Pipeline Analysis
Chapter 4. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Biomarker Estimates & Trend Analysis
4.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Biomarker Movement Analysis
4.2. Circulating Tumor Dna (Ctdna)
4.3. Circulating Tumor Cells (Ctcs)
4.4. Exosomes/Microvesicles
4.5. Circulating Proteins
Chapter 5. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Technology Estimates & Trend Analysis
5.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Technology Movement Analysis
5.2. NGS (Next-Generation Sequencing)
5.3. PCR-Based Assays (Digital Pcr, Rt-Pcr)
5.4. Microarray
5.5. Epigenomics / Methylation Assays
5.6. Others
Chapter 6. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Cancer Estimates & Trend Analysis
6.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Cancer Movement Analysis
6.2. Lung Cancer
6.3. Breast Cancer
6.4. Colorectal Cancer
6.5. Prostate Cancer
6.6. Others
Chapter 7. Liquid Biopsy For Early Cancer Detection And Monitoring Market: End Use Estimates & Trend Analysis
7.1. Liquid Biopsy For Early Cancer Detection And Monitoring Market: End Use Movement Analysis
7.2. Hospitals
7.3. Diagnostic Laboratories
7.4. Others
Chapter 8. Liquid Biopsy For Early Cancer Detection And Monitoring Market: Regional Business Analysis
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.3. Key Company Market Share Analysis, 2024
9.4. Company Heat Map Analysis
9.5. Company Profiles

• GRAIL, Inc.
• Exact Sciences Corporation
• AnchorDx
• Burning Rock Biotech Limited
• GENECAST
• Guardant Health
• Myriad Genetics, Inc.
• Elypta AB
• Lucence Health Inc.
• Freenome Holdings, Inc.
• Oncimmune

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Liquid Biopsy For Early Cancer Detection And Monitoring Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN06102025004107003653ID1110156363